RE:RE:Financials updateHonestAbe wrote: Only the last month of June had any significance so the financials this past quarter was not representative and irrelevant.
However, folks were disappointed in patient growth to just over 9,000 up to Oct 27, from 7,700 (Aug 31), which is a significant slow down and a disturbing trend if it persists into the fourth calender quarter.
Sold 257,080g @ $5.60 (Apr 1 to June30) Sold 556,000g @ $6.32 (Jul 1 to Oct 27) These average selling prices are quite a bit lower than their peers.
Investors and speculators bid up this stock to crazy multiples due to the impressive growth up to Aug 31. If the Alberta market turns out to be saturated and growth stalls then it would be worrisome if the sky high multiple drops and shares get repriced accordingly.
Despite management's best spin on reaching 9,000 patients, the reality is they gloss over the significant declining percentage growth rate on a monthly sequential basis since Jul 31.
May 31: 4500, Jun 30: 6,500, Aug 31: 7,700, Sep 30: prob 8,400, Oct 27: 9,000. Investors were expecting minimum 10,000 patients by end of Oct. And their production data does not add up to their current capacity in outlining a demand exceeds supply scenario. Sky high multiples getting pulled out from this stock and it will likely remain in a 1.50-$2 range unless further updates change this sentiment.